NWBO
Northwest Biotherapeutics, Inc. [NWBO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NWBO Stock Summary
Top 10 Correlated Stocks
NWBO
In the News
NWBO Financial details
Company Rating
Sell
Market Cap
618.78M
Income
-62.23M
Revenue
1.93M
Book val./share
-0.04
Cash/share
0
Dividend
-
Dividend %
-
Employees
25
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-9.15
Forward P/E
-
PEG
1.59
P/S
359.78
P/B
-11.32
P/C
-
P/FCF
-14.79
Quick Ratio
0.14
Current Ratio
0.17
Debt / Equity
-0.88
LT Debt / Equity
-0.43
-
-
EPS (TTM)
-0.06
EPS next Y
-
EPS next Q
-
EPS this Y
-57%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
5.99%
Revenue last 5Y
-4.33%
Revenue Q/Q
9.61%
EPS Q/Q
-2.38%
-
-
-
-
SMA20
-
SMA50
-10.34%
SMA100
-36.59%
Inst Own
0.04%
Inst Trans
0.16%
ROA
-256%
ROE
104%
ROC
3.3%
Gross Margin
100%
Oper. Margin
-2809%
Profit Margin
-3865%
Payout
-1%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.4-1.09
52W High
-
52W Low
-
RSI
44.22
Rel Volume
0.63
Avg Volume
1.79M
Volume
1.12M
Perf Week
-5.56%
Perf Month
-11.55%
Perf Quarter
-23.9%
Perf Half Y
-22.63%
-
-
-
-
Beta
-0.698
-
-
Volatility
0.01%, 0.03%
Prev Close
1.78%
Price
0.51
Change
0.97%
NWBO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.04 | -0.74 | 0.21 | -0.13 | -0.06 | |
| Operating cash flow per share | -0.06 | -0.04 | -0.04 | -0.05 | -0.05 | |
| Free cash flow per share | -0.06 | -0.05 | -0.05 | -0.05 | -0.05 | |
| Cash per share | 0 | 0.01 | 0.02 | 0.01 | 0 | |
| Book value per share | -0.08 | -0.5 | -0.14 | -0.13 | -0.04 | |
| Tangible book value per share | -0.08 | -0.5 | -0.14 | -0.13 | -0.04 | |
| Share holders equity per share | -0.08 | -0.5 | -0.14 | -0.13 | -0.04 | |
| Interest debt per share | 0.04 | 0.04 | 0.05 | 0.03 | 0.04 | |
| Market cap | 118.48M | 1.11B | 611.46M | 796.94M | 789.48M | |
| Enterprise value | 136.14M | 1.12B | 634.23M | 816.22M | 832.91M | |
| P/E ratio | -5.03 | -2.06 | 3.41 | -5.82 | -12.61 | |
| Price to sales ratio | 49.16 | 859.37 | 608.42 | 473.52 | 408.63 | |
| POCF ratio | -3.72 | -34.57 | -15.97 | -15.1 | -14.72 | |
| PFCF ratio | -3.68 | -28.67 | -13.8 | -14.31 | -13.83 | |
| P/B Ratio | -2.72 | -3.06 | -4.93 | -6.22 | -16.81 | |
| PTB ratio | -2.72 | -3.06 | -4.93 | -6.22 | -16.81 | |
| EV to sales | 56.49 | 867.02 | 631.08 | 484.98 | 431.11 | |
| Enterprise value over EBITDA | -4.96 | -12.99 | -12.02 | -12.43 | -15.49 | |
| EV to operating cash flow | -4.27 | -34.88 | -16.56 | -15.47 | -15.53 | |
| EV to free cash flow | -4.23 | -28.92 | -14.31 | -14.66 | -14.59 | |
| Earnings yield | -0.2 | -0.49 | 0.29 | -0.17 | -0.08 | |
| Free cash flow yield | -0.27 | -0.03 | -0.07 | -0.07 | -0.07 | |
| Debt to equity | -0.41 | -0.05 | -0.31 | -0.2 | -0.88 | |
| Debt to assets | 1.98 | 0.6 | 0.94 | 0.84 | 1.47 | |
| Net debt to EBITDA | -0.64 | -0.11 | -0.43 | -0.29 | -0.81 | |
| Current ratio | 0.08 | 0.04 | 0.13 | 0.07 | 0.09 | |
| Interest coverage | -9.23 | -10.14 | -10.52 | -11.07 | -10.04 | |
| Income quality | 1.57 | 0.06 | -0.21 | 0.5 | 0.86 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 6.76 | 42.03 | 33.23 | 19.82 | 15.38 | |
| Research and developement to revenue | 5.64 | 26.05 | 20.21 | 21.1 | 14.35 | |
| Intangibles to total assets | 0 | 0.06 | 0.05 | 0.06 | 0.07 | |
| Capex to operating cash flow | 0.01 | 0.21 | 0.16 | 0.05 | 0.06 | |
| Capex to revenue | -0.15 | -5.12 | -5.99 | -1.72 | -1.78 | |
| Capex to depreciation | 1.2 | -15.55 | -10.26 | -1.93 | -1.98 | |
| Stock based compensation to revenue | 0.76 | 40.44 | 15.42 | 7.31 | 2.28 | |
| Graham number | 0.27 | 2.89 | 0.81 | 0.62 | 0.23 | |
| ROIC | 1.58 | 0.26 | 0.64 | 0.9 | 39.2 | |
| Return on tangible assets | -2.58 | -17.38 | 4.68 | -4.65 | -2.41 | |
| Graham Net | -0.09 | -0.53 | -0.17 | -0.15 | -0.07 | |
| Working capital | -37.99M | -366.91M | -116.48M | -116.58M | -41.08M | |
| Tangible asset value | -43.57M | -364.87M | -125.91M | -130.02M | -48.89M | |
| Net current asset value | -49.5M | -380.34M | -146.86M | -150M | -70.8M | |
| Invested capital | -0.41 | -0.05 | -0.31 | -0.2 | -0.88 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 13.64M | 9.97M | 11.85M | 14.29M | 15.72M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 186.04 | 138.28 | 196.75 | 4.16K | 2.9K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 1.96 | 2.64 | 1.86 | 0.09 | 0.13 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.54 | 1.48 | -1.44 | 1.07 | 1.33 | |
| Capex per share | 0 | -0.01 | -0.01 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.03 | -0.01 | -0.01 | -0.02 | -0.02 | |
| Operating cash flow per share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | |
| Free cash flow per share | -0.01 | -0.01 | -0.01 | -0.01 | -0.02 | |
| Cash per share | 0.01 | 0.01 | 0 | 0.01 | 0 | |
| Book value per share | -0.12 | -0.05 | -0.06 | -0.06 | -0.04 | |
| Tangible book value per share | -0.12 | -0.05 | -0.06 | -0.06 | -0.04 | |
| Share holders equity per share | -0.12 | -0.05 | -0.06 | -0.06 | -0.04 | |
| Interest debt per share | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | |
| Market cap | 838.16M | 671.81M | 629.58M | 1.03B | 811.97M | |
| Enterprise value | 857.44M | 696.99M | 658.92M | 1.06B | 855.4M | |
| P/E ratio | -5.63 | -17.2 | -10.89 | -13.51 | -10.73 | |
| Price to sales ratio | 1.4K | 763.42 | 3.13K | 2.54K | 1.82K | |
| POCF ratio | -94.72 | -59.78 | -54.65 | -74.14 | -47.88 | |
| PFCF ratio | -76.13 | -53.44 | -49.3 | -71.88 | -46.73 | |
| P/B Ratio | -6.54 | -12 | -10.32 | -15.85 | -17.28 | |
| PTB ratio | -6.54 | -12 | -10.32 | -15.85 | -17.28 | |
| EV to sales | 1.44K | 792.03 | 3.28K | 2.62K | 1.92K | |
| Enterprise value over EBITDA | -48.27 | -55.26 | -50.46 | -76.91 | -58.11 | |
| EV to operating cash flow | -96.9 | -62.02 | -57.19 | -76.39 | -50.44 | |
| EV to free cash flow | -77.89 | -55.44 | -51.6 | -74.06 | -49.23 | |
| Earnings yield | -0.04 | -0.01 | -0.02 | -0.02 | -0.02 | |
| Free cash flow yield | -0.01 | -0.02 | -0.02 | -0.01 | -0.02 | |
| Debt to equity | -0.2 | -0.56 | -0.5 | -0.57 | -0.88 | |
| Debt to assets | 0.84 | 0.95 | 1.08 | 1.19 | 1.47 | |
| Net debt to EBITDA | -1.09 | -2 | -2.25 | -2.27 | -2.95 | |
| Current ratio | 0.07 | 0.21 | 0.12 | 0.17 | 0.09 | |
| Interest coverage | -14.89 | -12.62 | -10.43 | 8.28 | -12.2 | |
| Income quality | 0.31 | 1.06 | 0.8 | 0.75 | 0.9 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | -0.04 | 0 | 0 | |
| Sales general and administrative to revenue | 15.78 | 7.94 | 37.63 | 17.32 | 18.28 | |
| Research and developement to revenue | 15.66 | 7.8 | 30.92 | 17.74 | 16.75 | |
| Intangibles to total assets | 0.06 | 0.06 | 0.07 | 0.06 | 0.07 | |
| Capex to operating cash flow | 0.24 | 0.12 | 0.11 | 0.03 | 0.02 | |
| Capex to revenue | -3.62 | -1.51 | -6.21 | -1.08 | -0.94 | |
| Capex to depreciation | -5.65 | -3.32 | -2.97 | -0.89 | -0.99 | |
| Stock based compensation to revenue | 4.28 | 1.06 | 1.38 | 4 | 3.54 | |
| Graham number | 0.31 | 0.1 | 0.13 | 0.15 | 0.12 | |
| ROIC | 0.25 | 0.6 | 0.58 | 0.58 | 10.69 | |
| Return on tangible assets | -1.27 | -0.32 | -0.54 | -0.65 | -0.73 | |
| Graham Net | -0.14 | -0.08 | -0.08 | -0.08 | -0.06 | |
| Working capital | -116.58M | -35.22M | -35.28M | -40.77M | -41.08M | |
| Tangible asset value | -130.02M | -57.9M | -62.95M | -67.04M | -48.89M | |
| Net current asset value | -150M | -79.36M | -84.83M | -88.16M | -70.8M | |
| Invested capital | -0.2 | -0.56 | -0.5 | -0.57 | -0.88 | |
| Average receivables | 0 | 0 | 0 | 305K | 305K | |
| Average payables | 15.8M | 19.14M | 19.65M | 17.85M | 15.42M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 135.22 | 0 | |
| Days payables outstanding | 3.69K | 4.62K | 3.99K | 3.14K | 2.95K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0.67 | 0 | |
| Payables turnover | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.29 | 0.17 | 0.24 | 0.29 | 0.4 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
NWBO Frequently Asked Questions
What is Northwest Biotherapeutics, Inc. stock symbol ?
Northwest Biotherapeutics, Inc. is a US stock , located in Bethesda of Md and trading under the symbol NWBO
What is Northwest Biotherapeutics, Inc. stock quote today ?
Northwest Biotherapeutics, Inc. stock price is $0.51 today.
Is Northwest Biotherapeutics, Inc. stock public?
Yes, Northwest Biotherapeutics, Inc. is a publicly traded company.
Company Profile
- Volume Average 1.79M
- Market Capitalization 618.78M
- Employee 25
- CEO Ms. Linda F. Powers J.D.
- Headquarters Bethesda,MD,US
- IPO Date 2001-12-14
-
Website
https://www.nwbio.com 
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
